Celltrion Pharm's Cumulative Q3 Sales and Operating Profit Surpass Last Year's (Update)

[Asia Economy Reporter Seo So-jung] Celltrion Pharm (CEO Seo Jung-soo) announced on the 15th through its earnings disclosure that it recorded sales of 90.9 billion KRW, operating profit of 13 billion KRW, and net profit of 8.92 billion KRW based on the Q3 financial statements.

This represents an increase of 38.8% in sales, and 122.3% and 122.7% in operating profit and net profit respectively compared to the same period last year.

In particular, cumulative sales and operating profit up to Q3 this year reached 275.19 billion KRW and 39.27 billion KRW respectively, already surpassing last year's total sales of 235.5 billion KRW and operating profit of 23.6 billion KRW.

The flagship product, the liver disease treatment 'Godeks', recorded sales of over 17.8 billion KRW, while diabetes treatments 'Nesina' and 'Ectos', and hypertension treatment 'Idalbi', which began full-scale sales this year, steadily generated sales. In the biopharmaceutical sector, autoimmune disease treatment 'Remsima' and blood cancer treatment 'Truxima' also contributed to performance growth with strong sales.

Celltrion Pharm plans to accelerate growth by expanding sales of diabetes and hypertension treatments acquired from Takeda products, as well as the autoimmune disease treatment 'RemsimaSC', which was introduced domestically for the first time this year, while achieving record-high cumulative sales and operating profit as of Q3. In particular, RemsimaSC aims to complete the review by the domestic top-tier general hospital DC (New Drug Review Committee) within the year and focus on supply and market share expansion. As of November, RemsimaSC has passed DC approval at about 70 top-tier general hospitals nationwide.

Celltrion Pharm plans to strengthen both online and offline marketing for existing products while focusing on expanding its product lineup. Recently, the Humira biosimilar 'Uplima' and Alzheimer's dementia treatment 'Donerion Patch', which have obtained domestic product approval, are preparing for sequential launches.

Uplima, expected to be launched first, is the only high-concentration formulation among approved Humira biosimilars, improving administration convenience by removing citrate, which causes pain. The Alzheimer's dementia treatment Donerion Patch also recently obtained final product approval from the Ministry of Food and Drug Safety this month and is proceeding with procedures for domestic launch.

A Celltrion Pharm official said, "While chemical and bio flagship products continue steady growth, the smooth market entry and market share expansion of new products are expected to sustain the growth trend for the time being. For the remainder of this year, we will strengthen market share expansion and cost management of flagship products and thoroughly prepare in advance for new products scheduled to launch in the domestic market."

This content was produced with the assistance of AI translation services.